FDA clears Perspectum's liver cancer decision tool

The U.S. Food and Drug Administration (FDA) has cleared image analysis software developer Perspectum's Hepatica surgical decision-support tool for liver cancer.

Hepatica is a precision oncology decision-support tool for liver cancer. Image courtesy of Perspectum.

Surgery is a key liver cancer treatment option, and accurate presurgical staging is crucial, according to Perspectum. Hepatica uses quantitative, multiparametric MRI data to produce a liver health assessment that allows clinicians to make more informed decisions before surgery and thus improve postsurgery outcomes, the company said.